DGAP-Adhoc 1186 0 Kommentare STADA Arzneimittel AG: Significant renewal of Supervisory Board brought forward by two years - Annual General Meeting 2016 postponed to August 26, 2016

STADA Arzneimittel AG / Key word(s): Miscellaneous

22.05.2016 15:13

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Bad Vilbel, May 22, 2016 - The Supervisory Board of STADA Arzneimittel AG
resolved today to bring forward by two years the originally planned
election for 2018 of at least three shareholder representatives. The term
of office of the new shareholder representatives shall be five years. The
purpose of this realignment of the Supervisory Board is to further
strengthen STADA's successful international growth strategy for generics
and OTC products.

The candidates, who will be proposed for election at the Annual General
Meeting 2016, will be identified by a nomination committee of the
Supervisory Board with the support of external advisors and nominated by
the Supervisory Board. The nomination committee will be chaired by Dieter
Koch. In order to find the best-possible candidates for STADA, a structured
selection process has been put in place including a set of criteria that
includes professional expertise, personal qualification and independence
while taking into account the recommendations in various codes and rules of
good corporate governance.

The Executive Board has decided to postpone the Annual General Meeting
originally scheduled for June 9, 2016 to August 26, 2016 in order to ensure
an orderly and transparent process for the selection of candidates and for
the preparation of the election of the new Supervisory Board members.
Although the postponement implies that the announcements made in the
Federal Gazette of April 28 and May 17, 2016 concerning the Annual General
Meeting agenda no longer apply, the Executive Board and Supervisory Board
nevertheless expect at the present time that - with the exception of the
nomination proposals for the Supervisory Board elections - the previously
published agenda will remain unchanged for the rescheduled Annual General
Meeting.

Additional information for analysts:
STADA Arzneimittel AG / Investor Relations / Stadastraße 2-18 / 61118 Bad
Vilbel - Germany /
Tel.: +49 (0) 6101 603-113 / Fax: +49 (0) 6101 603-215 / E-mail:
ir@stada.de

Additional information for journalists:
STADA Arzneimittel AG / Media Relations / Stadastraße 2-18 / 61118 Bad
Vilbel - Germany /
Tel.: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-mail:
press@stada.de

Or visit us in the Internet at www.stada.com.

22.05.2016 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap.de

---------------------------------------------------------------------------

Language: English
Company: STADA Arzneimittel AG
Stadastraße 2-18
61118 Bad Vilbel
Germany
Phone: +49 (0)6101 603- 113
Fax: +49 (0)6101 603- 506
E-mail: communications@stada.de
Internet: www.stada.de
ISIN: DE0007251803, DE0007251845,
WKN: 725180, 725184,
Indices: MDAX
Listed: Regulated Market in Dusseldorf, Frankfurt (Prime Standard);
Regulated Unofficial Market in Berlin, Hamburg, Hanover,
Munich, Stuttgart; Terminbörse EUREX

End of Announcement DGAP News-Service

---------------------------------------------------------------------------